相关实验视频

Updated: Jul 3, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

一种潜在的双价mRNA疫苗候选人可以保护RSV和SARS-CoV-2感染

Namei Wu¹, Jiachen Zhang², Yanqiong Shen²

¹Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, P.R. China; School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, P.R. China.

Molecular therapy : the journal of the American Society of Gene Therapy

|February 11, 2024

概括

一种新的双价疫苗为SARS-CoV-2提供了Omicron尖峰和RSV融合蛋白的mRNA,可以保护两种病毒. 这种单一疫苗的方法表明,它有望预防多种传染病.

科学领域:

免疫学免疫学免疫学
疫苗学疫苗学疫苗学
病毒学病毒学

背景情况:

来自SARS-CoV-2和RSV感染的全球健康威胁是显著的.
同时感染多种呼吸道病毒会增加疾病的严重程度.
现有的疫苗针对单个病原体,需要多次接种疫苗.

研究的目的:

开发和评估一种针对SARS-CoV-2 Omicron和RSV的双价mRNA疫苗 (SF-LNP).
在动物模型中评估双价疫苗的免疫性和保护功效.
在双价疫苗设计中解决和提供抗原竞争的解决方案.

主要方法:

开发一种脂质纳米粒子 (LNP) 配方,为SARS-CoV-2尖端 (S) 和RSV融合 (F) 蛋白提供mRNA.
用SF-LNP疫苗对BALB/c小鼠和仓鼠进行免疫接种.
对S和F蛋白特异性抗体和细胞免疫反应的评估.
对活体SARS-CoV-2 Omicron和RSV挑战的保护评估.

主要成果:

在小鼠中,SF-LNP诱导了强大的S-和F-蛋白特定结合抗体和细胞免疫反应.
用SF-LNP免疫接种在小鼠中提供了对RSV感染的保护.
通过SF-LNP免疫接种,保护子免受SARS-CoV-2 Omicron感染.
该研究确定并提供了一个解决方案,用于双价疫苗的抗原竞争.

结论:

一个单一的双价mRNA疫苗 (SF-LNP) 可以同时诱导针对SARS-CoV-2 Omicron和RSV的免疫反应.
在临床前模型中,SF-LNP疫苗证明了对两种病毒的保护性有效性.
这项研究提出了一个可行的策略,用于开发针对多种传染病的多价值疫苗.

关键词:

抗原竞争抗原竞争这是一种双价疫苗.脂质纳米颗粒是一种纳米粒子.它们是mRNARNA.呼吸道传染病感染性疾病呼吸道同胞性病毒严重急性呼吸系统综合征新冠病毒2

更多相关视频

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Leaky Scanning

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...